Novo Nordisk A/S (NYSE: NVO) has recently received a number of price target changes and ratings updates:

  • 12/3/2019 – Novo Nordisk A/S was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 11/27/2019 – Novo Nordisk A/S was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating.
  • 11/22/2019 – Novo Nordisk A/S was downgraded by analysts at Pareto Securities from a “buy” rating to a “hold” rating.
  • 11/18/2019 – Novo Nordisk A/S was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating.
  • 11/18/2019 – Novo Nordisk A/S was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating.
  • 11/1/2019 – Novo Nordisk A/S was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 10/5/2019 – Novo Nordisk A/S was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.

Shares of Novo Nordisk A/S stock opened at $56.02 on Tuesday. The business’s fifty day simple moving average is $55.25 and its 200 day simple moving average is $51.52. The firm has a market capitalization of $132.96 billion, a P/E ratio of 22.23, a price-to-earnings-growth ratio of 2.26 and a beta of 0.61. Novo Nordisk A/S has a 12 month low of $43.60 and a 12 month high of $58.01. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. The firm had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.55 billion. Analysts predict that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.

Several large investors have recently modified their holdings of NVO. Oppenheimer & Co. Inc. raised its position in Novo Nordisk A/S by 0.4% in the third quarter. Oppenheimer & Co. Inc. now owns 49,188 shares of the company’s stock worth $2,544,000 after acquiring an additional 201 shares during the period. Pinnacle Bank raised its stake in shares of Novo Nordisk A/S by 21.7% in the third quarter. Pinnacle Bank now owns 1,140 shares of the company’s stock valued at $59,000 after buying an additional 203 shares during the period. OmniStar Financial Group Inc. lifted its position in shares of Novo Nordisk A/S by 0.3% during the 3rd quarter. OmniStar Financial Group Inc. now owns 65,282 shares of the company’s stock valued at $3,375,000 after buying an additional 204 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Novo Nordisk A/S by 0.3% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 66,336 shares of the company’s stock valued at $3,386,000 after buying an additional 219 shares during the last quarter. Finally, Sunbelt Securities Inc. lifted its position in shares of Novo Nordisk A/S by 1.9% during the 2nd quarter. Sunbelt Securities Inc. now owns 12,959 shares of the company’s stock valued at $661,000 after buying an additional 238 shares during the last quarter. 7.32% of the stock is currently owned by institutional investors.

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: What is Put Option Volume?

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.